Sibylla
Trento, IT · 42 employees on LinkedIn · 8 known investors
Find your way into Sibylla
212 people in our graph share verified history with the Sibylla team — schools, employers, funds. One of them is your warm intro.
Alessio Quagliniunlockedknows Emiliano Biasini · together at Sapienza Università di Roma (overlapped)
knows the team · via University of Houston
×8knows the team · via Stony Brook University
knows the team · via Sapienza Università di Roma
knows the team · via Sibylla
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution. The company focuses on protein misfolding diseases, particularly prion diseases.
Founders & leadership
EB
Emiliano BiasiniinCo-founderEmiliano Biasini is a research scientist and biochemistry professor who leads the Dulbecco Telethon Laboratory of Prions & Amyloids at the University of Trento, where he investigates protein misfolding mechanisms and neurodegeneration. Co-founder of Sibylla Biotech, he applies expertise in biochemistry, molecular biology, and biophysics to develop drug discovery technologies for prion diseases.
PF
Pietro FaccioliinCo-founderPietro Faccioli holds a background in theoretical high-energy physics and has applied statistical and quantum mechanics to biophysics problems, including non-equilibrium biomolecular transitions and quantum dynamics in biological molecular systems. He is co-founder of Sibylla Biotech, which develops computational approaches to study protein folding pathways.
GS
Giovanni SpagnolliinCo-founder, CTO
ML
Maria Letizia BarrecainCo-founderMaria Letizia Barreca is a medicinal chemist with expertise in molecular modeling, computational chemistry, and chemoinformatics; she is co-founder of Sibylla Biotech, which develops drug discovery technology for protein misfolding diseases.
GL
Graziano LolliCo-founder
Investors · 8
3B Future Health Fund✓ verifiedMonaco · $12M
CDP Venture Capital✓ verifiedRome
Seroba Life Sciences✓ verifiedDublin · $540K – $7.6M
V-Bio Ventures✓ verifiedGhent · $270K – $2.2M
Vertis SGR✓ verifiedNaples
VI Partners✓ verifiedAltendorf · $2.2M – $4.5M
Claris VenturesTurin
Indaco Venture PartnersreportedMilan
In the news
Frequently asked questions
- What does Sibylla do?
- Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution. The company focuses on protein misfolding diseases, particularly prion diseases.
- Who founded Sibylla?
- Sibylla was founded by Emiliano Biasini, Pietro Faccioli, Giovanni Spagnolli, Maria Letizia Barreca, Graziano Lolli.
- Who are Sibylla's investors?
- Sibylla's investors include 3B Future Health Fund, CDP Venture Capital, Seroba Life Sciences, V-Bio Ventures, Vertis SGR, VI Partners, Claris Ventures, Indaco Venture Partners.
- Where is Sibylla headquartered?
- Sibylla is headquartered in Trento, IT.